Browse the evidence

Lifestyle interventions including diet and exercise can reduce the incidence of Type 2 Diabetes in prediabetic individuals by up to 58%.

If you have prediabetes, aim to lose 5-7% of your body weight and exercise 150 minutes a week. This can reduce your risk of developing full-blown diabetes by more than half.

GLP-1 receptor agonists (GLP-1-RAs) produce significant weight loss (up to 14.9%) and improved glycemic control (HbA1c reduction 0.8-1.8%) in adults with obesity or type 2 diabetes through mechanisms involving delayed gastric emptying, increased satiety, and glucose-dependent insulin secretion.

If you have obesity or type 2 diabetes and lifestyle changes haven't been enough, GLP-1 medications like semaglutide or liraglutide are highly effective. They work by mimicking a hormone that tells your brain you're full and slows down digestion. Expect some stomach upset at first, but starting with a low dose and increasing slowly helps. These drugs can lead to significant weight loss (around 15% in some cases) and better blood sugar control, especially if you have heart disease risk factors.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces significant, dose-dependent weight loss in adults with obesity (BMI ≥30 or ≥27 with comorbidities) and type 2 diabetes, outperforming placebo, semaglutide, and insulin glargine.

Tirzepatide is a once-weekly injectable medication for obesity and type 2 diabetes that works by mimicking two gut hormones (GIP and GLP-1). It significantly reduces body weight (up to ~21% in clinical trials) and improves blood sugar control. It is more effective than semaglutide and insulin glargine for weight loss. Common side effects include nausea and diarrhea, which usually improve over time. It requires a prescription and medical supervision.

Treatment with GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide and liraglutide produces substantial body weight loss (exceeding 15%) and improves glucose control, leading to type 2 diabetes prevention and possible disease remission.

If you have obesity or type 2 diabetes, GLP-1 receptor agonists (like semaglutide or liraglutide) are highly effective treatments that can help you lose more than 15% of your body weight and improve blood sugar control. This can potentially lead to remission of type 2 diabetes. While lifestyle changes are important, they are often not enough on their own to maintain weight loss or prevent diabetes progression, making these medications a key part of modern management.

Maximum strength improvements are maximized by heavy loads (high % 1RM), whereas vertical jump performance is maximized by lighter loads (~30% 1RM) and power by low-to-moderate loads (40–70% 1RM).

To maximize strength, use heavy loads. To maximize jumping ability, use lighter loads around 30% of your one-rep max. For general power, use loads between 40-70% of your one-rep max. Do not use the same heavy load for all exercises.

Semaglutide (2.4 mg subcutaneous once weekly) produces significant weight loss in adults with obesity or overweight by reducing appetite and energy intake rather than increasing energy expenditure.

Semaglutide 2.4 mg injected once weekly, combined with lifestyle changes, leads to substantial weight loss (approx 15%) in adults with obesity. The primary mechanism is reduced appetite and food cravings, not increased metabolism. Be prepared for potential nausea, which is the most common reason people stop treatment.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, induces greater weight loss and improves glycemic control more effectively than GLP-1 RAs alone.

Tirzepatide (5-15 mg weekly) combines GIP and GLP-1 mechanisms to achieve higher weight loss (up to 21%) than GLP-1 drugs alone. It is a potent option for those who need maximum efficacy.

GLP-1 receptor agonists (semaglutide 2.4 mg, tirzepatide) produce significantly greater weight loss than older pharmacotherapies (liraglutide, orlistat, phentermine/topiramate) and provide cardiovascular benefits.

If lifestyle changes alone are insufficient, newer GLP-1 medications like semaglutide (2.4 mg weekly) offer significantly higher weight loss (approx. 15%) compared to older drugs. Discuss these options with your doctor, keeping in mind that cost and insurance coverage may be barriers.

Incretin-based therapies (liraglutide, semaglutide, tirzepatide) produce significant body weight reduction (≥5% in majority of patients) and reduce the 10-year relative risk of type 2 diabetes development by 60-69% in individuals with obesity.

If you have obesity or overweight with related health issues, incretin-based medications (like semaglutide or tirzepatide) are highly effective for significant weight loss and preventing type 2 diabetes. They work by mimicking hormones that regulate appetite and are taken weekly (or daily for liraglutide) alongside lifestyle changes. These are not quick fixes but long-term treatments requiring continuous use to maintain results.

Tirzepatide demonstrates superior body weight reduction compared to semaglutide 2.4 mg and liraglutide 3.0 mg in non-diabetic subjects with obesity.

Among incretin therapies, tirzepatide offers the greatest weight loss potential for non-diabetic individuals with obesity, outperforming semaglutide and liraglutide.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior body weight reduction and glycemic control compared to semaglutide, insulin degludec, and insulin glargine in patients with type 2 diabetes.

For patients with Type 2 Diabetes struggling with weight and blood sugar, Tirzepatide offers a once-weekly injection that has been shown to be more effective than semaglutide, insulin degludec, and insulin glargine in reducing both body weight and HbA1c. Treatment starts at a low dose (2.5 mg) and is titrated up to 5, 10, or 15 mg weekly to manage side effects. This therapy is particularly beneficial for those who have not achieved targets with oral medications or other injectables.

Tirzepatide promotes significant body weight loss in non-diabetic adults with obesity, with efficacy increasing with dose (5, 10, 15 mg).

For individuals with obesity who do not have Type 2 Diabetes, Tirzepatide is an approved once-weekly injection that has been shown to produce significant and clinically meaningful weight loss over 72 weeks. The medication is titrated starting at 2.5 mg and increased to 5, 10, or 15 mg weekly. It also improves blood pressure, waist circumference, and lipid profiles.

Subcutaneous semaglutide (0.5 mg and 1.0 mg) significantly reduces HbA1c and body weight in Type 2 Diabetes patients compared to placebo and other antidiabetic agents.

If you have Type 2 Diabetes, once-weekly subcutaneous semaglutide (0.5 mg or 1.0 mg) is a highly effective treatment for lowering blood sugar (HbA1c) and reducing body weight. It works better than many other standard diabetes medications and placebo. Be prepared for potential nausea or diarrhea, which are common but often mild and decrease over time.

Semaglutide (2.4 mg once-weekly subcutaneous) significantly reduces body weight in adults with obesity or overweight with comorbidities compared to placebo.

For adults with obesity or overweight who have at least one weight-related health issue (like high blood pressure or cholesterol), a once-weekly injection of semaglutide (2.4 mg) combined with lifestyle changes can lead to significant, sustained weight loss (averaging nearly 15% of body weight in trials). While gastrointestinal side effects like nausea are common, they often subside, and starting with a lower dose can help your body adjust.

Semaglutide (0.5-1.0 mg once-weekly subcutaneous) lowers HbA1c and reduces body weight more effectively than other common GLP-1 RAs (exenatide, dulaglutide, liraglutide) and SGLT-2 inhibitors (canagliflozin) in Type 2 Diabetes.

If you have Type 2 Diabetes, semaglutide (0.5-1.0 mg weekly) is a highly effective option that lowers blood sugar and promotes weight loss more effectively than several other common diabetes medications like exenatide, dulaglutide, or liraglutide. It can be used alone or combined with other drugs like metformin or insulin.

Semaglutide (2.4 mg/weekly) significantly reduces the risk of major adverse cardiovascular events (MACE) in patients with overweight or obesity without diabetes, while also producing substantial weight loss and improving heart failure symptoms in those with preserved ejection fraction.

If you have heart disease or high risk for it, along with excess weight, semaglutide (Ozempic/Wegovy) is a highly effective treatment. It is taken as a once-weekly injection, starting at a low dose and increasing over 4 months to 2.4 mg. It significantly lowers your risk of heart attack and stroke, helps you lose about 9-13% of your body weight, and improves heart failure symptoms if you have them. Common side effects like nausea are usually temporary and manageable.

Tirzepatide (5-15 mg weekly) significantly reduces body weight and HbA1c in patients with Type 2 Diabetes and obesity, outperforming semaglutide, insulin degludec, and insulin glargine.

Tirzepatide is a once-weekly injection for T2DM and obesity that works by mimicking gut hormones (GIP and GLP-1) to improve insulin sensitivity and reduce appetite. It produces greater weight loss and blood sugar control than existing GLP-1 drugs like semaglutide or insulin. Start with a low dose to manage side effects, titrating up every few weeks.

High-dose GLP-1 receptor agonists (semaglutide 2.4 mg/week) and dual GLP-1/GIP agonists (tirzepatide 15 mg/week) produce substantial weight loss (>15% and >20% respectively) in non-diabetic obese individuals, with efficacy maintained over 2 years.

For non-diabetic individuals with obesity, weekly injections of semaglutide (2.4 mg) or tirzepatide (15 mg), combined with a reduced-calorie diet and exercise, can lead to 15-20% body weight loss over two years. Expect initial gastrointestinal side effects like nausea, which usually subside within a few months as the dose is gradually increased.

GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and liraglutide produce significant weight loss and improve cardiovascular outcomes by acting as incretin mimetics that target G-protein-coupled receptors to regulate body fat and energy balance.

GLP-1 medications like semaglutide are highly effective for significant weight loss (approx. 15%) when combined with a reduced-calorie diet. They work by mimicking gut hormones to reduce appetite and slow digestion. Treatment requires weekly injections and gradual dose escalation to manage side effects like nausea. Because obesity is chronic, long-term use is often necessary to maintain results.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces superior weight loss compared to semaglutide and other comparators in patients with type 2 diabetes and obesity.

Tirzepatide is a dual-acting hormone medication (GIP/GLP-1) that offers even greater weight loss than semaglutide (up to 21% in trials). It is administered as a once-weekly injection, starting at a low dose and increasing every 4 weeks. It is particularly effective for patients with type 2 diabetes and obesity, improving both blood sugar and weight significantly more than other comparators.

A pragmatic prescribing pathway for liraglutide 3.0 mg using multiple stopping rules (≥5% weight loss at 16 weeks, ≥10% at 32 weeks, and ≥15% at 52 weeks) significantly increases the proportion of adults with obesity achieving ≥15% weight loss compared to standard specialist weight management services alone.

If you have a BMI of 35 or higher and conditions like high blood pressure or sleep apnea, ask your doctor about a specialized weight management program that includes liraglutide 3.0 mg. This medication is taken as a daily injection, starting at a low dose and increasing to 3 mg. A key part of this approach is 'stopping rules': if you don't lose enough weight at specific check-ups, the medication is stopped to save costs and avoid unnecessary side effects. This method helps ensure that only those who benefit continue treatment, leading to much better long-term weight loss results than lifestyle changes alone.

GLP-1 receptor agonists (specifically semaglutide and liraglutide) are the most effective pharmacological interventions for weight loss, producing significantly greater total body weight loss than other FDA-approved anti-obesity medications.

If you have obesity, lifestyle changes alone are rarely enough for long-term success due to your body's biological resistance. Semaglutide (Ozempic/Wegovy) is currently the most effective drug available, helping patients lose an average of 12.4% of their body weight when combined with diet and exercise. It requires a weekly injection. If cost is a barrier, discuss insurance coverage (sometimes available for diabetes) or cheaper alternatives like phentermine-topiramate with your doctor. The goal is to find a regimen you can tolerate and afford for the long term.

Phentermine-topiramate extended-release is a highly effective alternative for weight loss, particularly for patients who cannot use GLP-1 agonists, achieving high percentages of total body weight loss.

If GLP-1 drugs are too expensive or not covered by insurance, Phentermine-topiramate (Qsymia) is a strong alternative that can help you lose around 10-11% of your body weight. It is a daily pill. Be aware of potential side effects like irritability or sleep issues, which can often be managed by adjusting the dose or taking the medication earlier in the day. It is contraindicated if you have uncontrolled high blood pressure or a history of seizures.

Bariatric weight loss surgery is significantly more effective than pharmacotherapy and lifestyle modifications for long-term weight loss and improvement of comorbid conditions in eligible patients, yet remains severely underutilized.

If you have severe obesity (BMI ≥ 40, or ≥ 35 with health issues, or ≥ 30 with diabetes) and lifestyle changes haven't worked, bariatric surgery is the most effective long-term solution, far surpassing drugs and diet alone. It improves diabetes and heart health significantly. However, it is rarely recommended by doctors due to misconceptions about risk. If you meet the criteria, ask your doctor for a referral to a bariatric specialist.